A direct switch from MDI to the Omnipod 5 AID (automated insulin delivery; hybrid closed-loop) System produced clinically significant glucose improvements within 13 weeks, signalling a practical leap forward in improved diab
In automated insulin delivery (AID) (also known as hybrid closed-loop) systems, reliable connectivity between continuous glucose monitor (CGM) sensors and the insulin delivery device is essential.
The Omnipod 5 Automated Insulin Delivery (AID) System is a transformative step in diabetes care. The system merges the benefits and simplicity of a wearable, tubeless design with AID technology.
When making treatment decisions for type 1 diabetes (T1D), healthcare professionals increasingly rely on real-world data to understand how therapies perform outside of clinical trials. A recent study— Aleppo G et al. Diabetes Ther. 2023.
Helping people with type 1 diabetes (T1D) stay active has long been a balancing act. Exercise can improve metabolic health and quality of life but also increases the risk of glycaemic variability and hypoglycaemia.1,2